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Introduction: The aim of the study was to investigate repetitive fractional exhaled nitric oxide (FeNO)
measurements during high-dose radiation therapy (HDRT) and to evaluate the use of FeNO to predict
symptomatic radiation pneumonitis (RP) in patients being treated for non-small cell lung cancer (NSCLC).
Materials and methods: A total of 50 patients with NSCLC referred for HDRT were enrolled. FeNO was
measured at baseline, weekly during HDRT, one month- and every third month after HDRT for a one-
year follow-up period. The mean FeNO(visit 0-6) was calculated using the arithmetic mean of the baseline
and weekly measurements during HDRT. Patients with grade  2 of RP according to the Common
Terminology Criteria for Adverse Events (CTCAE) were considered symptomatic.
Results: A total of 42 patients completed HDRT and weekly FeNO measurements. Grade  2 of RP was
diagnosed in 24 (57%) patients. The mean FeNO(visit 0-6) ± standard deviation in patients with and without
RP was 15.0 ± 7.1 ppb (95%CI: 12.0–18.0) and 10.3 ± 3.4 ppb (95%CI: 8.6–11.9) respectively with signifi-
cant differences between the groups (p = 0.0169, 95%CI: 2.3–2.6). The leave-one-out cross-validated
cut-off value of the mean FeNO(visit 0-6)  14.8 ppb was predictive of grade  2 RP with a specificity of
71% and a positive predictive value of 78%.
Conclusions: The mean FeNO(visit 0-6) in patients with symptomatic RP after HDRT for NSCLC was signif-
icantly higher than in patients without RP and may serve as a potential biomarker for RP.
 2019 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
High-dose radiation therapy (HDRT) is the main treatment for
patients with localized non-small cell lung cancer (NSCLC) who
are ineligible for surgery [1,2]. One of the most serious side effects
of HDRT is radiation pneumonitis (RP), which is characterized by
inflammatory damage to the irradiated lung parenchyma and canlead to severe respiratory distress or even death [3]. The incidence
of RP ranges from 8 to 50% depending on the diagnostic criteria
[3–5]. One of the most frequently used diagnostic grading scale
is the Common Terminology Criteria for Adverse Events (CTCAE).
Typical symptoms of RP include cough, dyspnea, fever and fati-
gue, which usually occur between 4 and 12 weeks after the end of
radiotherapy [6]. In few cases RP develops during HDRT or shortly
afterwards. The earlier RP is observed, the more severe the grade
[7]. Treatment guidelines are based on nonrandomized clinical tri-
als [8] and recommend prednisolone 1 mg/kg per day for several
weeks [9].
104 W.M. Szejniuk et al. / Clinical and Translational Radiation Oncology 19 (2019) 103–109Candidate predictive biomarkers lack satisfactory sensitivity
and specificity [10–12]. Dose-volume histogram (DVH)-based
HDRT allows minimization of side effects for organs at risk [5].
However, DVH estimation cannot assess the individual risk of RP
[13]. Therefore, predictive markers are necessary.
One of the proposed markers of RP is fractional exhaled nitric
oxide (FeNO), which may be increased in patients with lung cancer
[14]. Some studies showed a decrease in FeNO after HDRT, with the
exception of patients with RP [15–18]. Measurement of FeNO is
noninvasive and reproducible [19–21], currently used to monitor
inflammation in asthma [22].
This pilot study explores the value of repetitive FeNO measure-
ments during HDRT to predict symptomatic RP in patients being
treated for NSCLC. The study was performed at the Department
of Oncology, Aalborg University Hospital, Denmark.2. Materials and methods
2.1. Patients
Patients with NSCLC verified by histopathology or cytology and
referred for HDRT were considered eligible. Staging was deter-
mined using the 8th edition of the tumor, node and metastasis
(TNM) classification system for NSCLC [23]. Chemotherapy was
administered according to the Danish National guidelines [1].
The exclusion criteria were previous thoracic radiotherapy, cystic
fibrosis or sarcoidosis. Each patient signed an informed consent
form before the enrolment. The follow-up period was censored at
12 months from HDRT or at the time of diagnosis of progressive
disease by computed tomography (CT) scan. The study was
performed in accordance with the principles of the Helsinki
declaration. The project was approved by the National Committee
of Health Ethics of North Denmark (reg. no N-20120029) and
reported to the Data Protection Agency in Denmark
(2008-58-0028).
2.2. Imaging assessment
Baseline CT or positron emission tomography-CT (PET-CT) of
the chest was performed on average within 8 weeks before the
HDRT. Follow-up CT scans were scheduled 4–6 weeks after the last
HDRT fraction was administered and every three months until
12 months after HDRT. All imaging was re-evaluated by one senior
consultant radiologist (ZTS) who was blinded to the clinical find-
ings. Each CT was analyzed according to the Response Evaluation
in Solid Tumors (RECIST) criteria version 1.1 [24].
2.3. Clinical assessment
Performance status (PS), weight, smoking status and adminis-
tration of medicine were reported at each visit. Clinical signs of
RP were investigated and assessed using the CTCAE version 4.
Grade 1 was defined as asymptomatic RP with no medical inter-
vention; grade 2 as symptomatic RP requiring steroid administra-
tion; grade 3 as severe symptomatic RP requiring oxygen
treatment; grade 4 as life-threatening RP with respiratory compro-
mise; and grade 5 as death due to RP [25].
2.4. High-dose radiation therapy
Target and normal tissue delineation and dose calculations
were performed on PET-CT scans. The delineation of gross tumor
volume (GTV), clinical target volume (CTV) and planning target
volume (PTV) was performed according to the International Com-
mission on Radiation Units & Measurements (ICRU 62) [26] andthe Danish National guidelines [1]. The radiotherapy dose plans
were calculated using the EclipseTM Treatment Planning System
(TPS) from Aria Oncology Information System, Varian Medical
System (California, USA). Plans were optimized using either three
dimensional (3D) conformal or intensity modulated radiotherapy
(IMRT). Due to changes in the TPS algorithm during the inclusion
period of the study, plans were recalculated using the anisotropic
analytic algorithm (AAA) 13.7 with fixed beam data. The prescribed
mean dose for the CTV was 60–66 Gray (Gy)/30–33 fractions/5
fractions per week with a target dose homogeneity within 95–
107%. Constraints to the organs at risk were as follows: mean lung
dose (MLD) < 20 Gy, V5 (percentage of lung volume exceeding
5 Gy)  60%, V20 (percentage of lung volume exceeding 20 Gy) 
40% for both lungs excluding GTV, V50 (percentage of heart volume
exceeding 50 Gy)  20% for the heart, global hotspot < 115%, total
dose of  66 Gy for the esophagus and  45 Gy for the spinal cord.2.5. Chemotherapy
Carboplatin (AUC 5) was administered intravenously (i.v.) on
day 1 and 60 mg/m2 of vinorelbine per os (p.o.) was administered
on day 1 and 8 every 3 weeks, and 3 cycles in total were given.
Patients treated concomitantly received HDRT simultaneously
with the second chemotherapy cycle. In the case of induction
chemotherapy, HDRT was delivered after 3–4 cycles. Chemother-
apy according to the Navelbine and Radiotherapy in Locally
Advanced Lung cancer [27] protocol was also allowed (induction
carboplatin 5 AUC i.v. on day 1 and vinorelbine 60 mg/m2 p.o. on
days 1 and 8 during the first cycle and 80 mg/m2 p.o. on days 1
and 8 during the second cycle followed by concomitant vinorelbine
(50 mg on three days of a week) during HDRT. If the patient was
considered not eligible for concomitant treatment, HDRT alone
was delivered.2.6. Fractional exhaled nitric oxide measurements
FeNOmeasurements were performed using chemiluminescence
analyzers (NIOX MINO and VERO; Aerocrine, Solna, Sweden).
The results were reported in parts per billion (ppb). A single FeNO
measurement was performed at baseline, followed by weekly mea-
surements during the six weeks of HDRT, 4–6 weeks after HDRT
and every third month for a one-year follow-up period. Patients
were instructed to inhale to near-total lung capacity and to exhale
afterwards with a constant flow rate of 50 ml/s for 10 s according
to the international guidelines [28]. The FeNO measurements were
performed before pulmonary function tests (PFTs) if those were
planned on the same day. The arithmetic mean FeNO of baseline
and weekly measurements during the HDRT were calculated for
every patient and named the mean FeNO(visit 0-6). Steroid treatment
and smoking status during radiation were registered.2.7. Pulmonary function tests
Spirometry and automatic lung parameter estimator (ALPE)
measurements were performed at baseline, one month after HDRT
and at the 12 month visit with additional ALPE measurements
made during the fourth week of HDRT. Baseline spirometry was
performed with a SPIDA spirometer, while during the follow-up
period, an Easy One spirometer was used. The forced expiratory
volume in 1 s (FEV1), forced vital capacity (FVC) and Tiffeneau-
Pinelli index (FEV1/FVC ratio) were registered. The ALPE measure-
ments were performed with an Essential (Mermaid Care,
Denmark) estimator [29].
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Longitudinal data were collected from 11 visits, including the
baseline visit. Patients with RP CTCAE grade  2 were defined as
the RP group while patients with RP CTCAE grade < 2 were allo-
cated to the non-RP group. Patient characteristics between the
groups were compared using the t-test, Mann-Whitney’s U test
or chi-square tests depending on whether the variables were con-
tinuous or categorical. The mean FeNO(visit 0-6) for each patient in
the RP and NRP groups was compared using the t-test after loga-
rithmic transformation. Univariate logistic regression was used to
test associations between clinical variables and RP. Statistically sig-
nificant variables from the univariate analyses were used in the
multivariate logistic regression analysis. The optimal cut-off value
of FeNO(visit 0-6) as a predictor of symptomatic RP was obtained as
the value that maximized the sum of sensitivity and specificity
(i.e., Youden’s index) and visualized by the area under the receiver
operating curve (AUC). Cross-validation of the sensitivity, speci-
ficity and positive and negative predictive values with leave-one-
out was performed to test the generalizability of Youden’s index
as a predictor for symptomatic RP. Tests with a two-sided
p < 0.05 were deemed statistically significant. All computations
were performed using the statistical program Stata, version 14.2.
3. Results
Between October 2012 and December 2016, 50 patients were
included in the study (Fig. 1). The results are based on data from
42 patients who completed the treatment (Table 1). In 24 patients,
CTCAE grade  2 RP was diagnosed (23 grade 2, 1 grade 3). The
average time to RP diagnosis was 81 days (range, 3–166; median,
69 days) after administration of the last HDRT fraction. Oral steroid
treatment unrelated to RP (due to nausea / fatigue) during HDRT
was administered in four and one patient in the RP and non-RP
groups, respectively. One patient in the RP group was treated for
asthma. Nineteen patients completed the follow-up period of
12 months without recurrence or progressive disease (PD) (Fig. 1).
The mean FeNO(visit 0-6) ± standard deviation for RP patients was
15.0 ± 7.1 ppb (95%CI: 12.0–18.0) compared to that for non-RP
patients of 10.3 ± 3.4 ppb (95%CI: 8.6–11.9). The difference
between the groups was statistically significant after log-
transformation (p = 0.017, 95%CI: 2.3–2.6) (Fig. 2). The difference
in the mean FeNO(visit 0-6) remained statistically significant after
adjustment for non-RP-related steroid treatment during HDRTFig. 1. Patient inclus(OR 6.3, 95%CI: 1.2–33.6, p = 0.03) and dose of radiation therapy
(OR 6.6, 95%CI: 1.0–43.1, p = 0.05) in the multivariate analysis.
However, after adjustment for smoking status, the difference in
the mean FeNO(visit 0-6) showed a statistical trend (OR 4.87, 95%
CI: 0.85–27.9, p = 0.075). Ten patients who smoked during HDRT
had mean FeNO(visit 0-6) of 9.3 ppb compared to non-smokers with
FeNO(visit 0-6) of 14.1 ppb. The predictive value of the mean
FeNO(visit 0-6) for RP was denoted as AUC = 0.73 (Fig. 3). The optimal
Youden’s index was 14.8 ppb, by yielding a sensitivity of 50% and a
specificity of 94%. After cross-validation of the cut-off value, the
mean FeNO(visit 0-6) of 14.8 ppb showed a sensitivity and specificity
for predicting symptomatic RP of 0.50 (0.31, 0.69) and 0.71 (0.42,
0.92), respectively. The positive predictive value was 0.78 (0.52,
0.94), and the negative predictive value was 0.42 (0.22, 0.63).
The mean of FeNO among patients who developed RP was
higher compared to the non-RP group and increased after HDRT
(Fig. 4A), becoming most distinct 4.5 months after HDRT (Table 2).
The differences in the mean FeNO between the groups were statis-
tically significant despite high-dose steroid treatment for RP
(Fig. 4B). Only patients who developed RP showed a statistically
significant increase in FeNO compared to their baseline measure-
ments 4.5 months after HDRT (p = 0.02).
The majority of patients were treated with 66 Gy in 33 frac-
tions. Neither the radiation dose, tumor localization (upper versus
middle or lower lobe), nor the affected lung (left versus right) had
statistically significant impact on development of RP. There were 5
cases of post-operative HDRT in the RP group compared to only one
case of post-operative HDRT in the non-RP group (Table 1). The dif-
ferences in dosimetric parameters, the mean MLD and V5 to V60
were not statistically significant between the RP and non-RP
groups (Table 3).
The difference between the baseline FEV1 and FEV1/FVC was
not statistically significant in the RP and non-RP groups (p = 0.2
in both). The change in FEV1 after HDRT was not significant in
either of the groups (p = 0.18). The ALPE measurements were per-
formed in 35 patients at baseline. Seven patients had low baseline
oxygen normalization pressure, three of them developed RP, and
two of those had ventilation/perfusion mismatch.
The majority of patients were either active or previous smok-
ers. There was no statistically significant difference in smoking
history between the RP and non-RP groups (Table 1). The average
number of pack-years was comparable between the groups, with
43.5 pack years in the RP group versus 52.5 in the non-RP group
(p = 0.3).ion flow-chart.
Table 1
Patient characteristics related to radiation pneumonitis (RP).
CTCAE grade  2
RP (n = 24)
CTCAE grade < 2
RP (n = 18)
p-Value
Age (y)
Median 66 64 p = 0.93
Range 40–78 45–74
Gender
Female 10 8 p = 1.00
Male 14 10
Performance status
0 13 12 p = 0.53
1 11 6
Smoking status
Never 2 0 p = 0.07
Previous 19 11
Current (during HDRT) 3 7
Histopathology
Adenocarcinoma 11 7 p = 0.92
Squamous cell carcinoma 8 7








No tumor (postop. HDRT) 5 1
Steroid treatment during HDRT




Induction 6 3 p = 0.45
None 2 0
Radiation therapy dose
60 Gy/30 fx 6 7 p = 0.50
66 Gy/33 fx 18 11
Radiation therapy type
3D conformal 23 17 p = 0.68
IMRT 1 1
HDRT side
Left 7 6 p = 1.00
Right 17 12
HDRT lobe localization
Upper 12 11 p = 0.54
Middle/lower 12 7
CTCAE – Common Terminology Criteria for Adverse Events; RP – radiation pneu-
monitis; HDRT – high-dose radiation therapy; NSCLC – non-small cell lung cancer;
TNM – tumor, node, metastasis; IMRT – intensity-modulated radiation therapy.
Fig. 2. The mean FeNO(visit 0–6) for the non-radiation pneumonitis (0 – non-RP)





















Fig. 3. Area under the receiver operating characteristic (ROC) curve (AUC) for the
cut-off value of 14.8 ppb for the mean FeNO(visit 0–6).
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Increased FeNO in exhaled air is normally observed in patients
with asthma, eosinophilic airway inflammation or high level of
allergen exposure [28]. A physiologically elevated FeNO has been
postulated to be a result of activation of a nitric oxide synthase,
which activity remains increased in alveolar macrophages for three
months after irradiation [30]. In our study, the levels of FeNO after
HDRT were increased in both groups of patients, independent of
RP. Interestingly, the levels of FeNO were already higher in patients
with RP at baseline and throughout the HDRT, with the most signif-
icant increase in FeNO occurring approximately 4 months after
HDRT. The FeNO(visit 0-6) remained statistically significant even if
accounting for radiation dose. Asthma was diagnosed in one patient
from the RP group. However, this patient had a FeNO(visit 0-6)
< 10 ppb, which did not bias the value of the mean FeNO for the
RP group. The standard deviations of the weekly FeNO measure-
ments for every patient were higher than those reported in the
literature, suggesting that weekly measurements can vary more
than repetitive measurements and are of lower precision than3 ppb [19]. The FeNO measurements one month or later after the
end of HDRT were not useful for predicting RP and therefore can
be avoided in practice.
Dynamic changes in FeNO were described by Yamazaki et al.
[31], who showed a decrease in FeNO immediately after HDRT in
both groups of patients with and without RP. The authors calcu-
lated a threshold of the FeNO ratio (FeNO/minimum value of FeNO
during HDRT) of 1.4 for RP symptoms, which had 100% sensitivity
and 52% specificity. These findings confirmed results from previous
studies of the predictive ability of an FeNO ratio > 1.4 to distinguish
asymptomatic from symptomatic RP patients [16,17]. Our study
cannot be used to reproduce the result from the mentioned studies
as the FeNO was not measured immediately after the end of HDRT.
However, the FeNO(visit 0-6) in our study showed a higher specificity
with AUC 0.73 compared previous studies.
Interestingly, FeNO levels were higher at baseline in patients
with RP and persisted throughout the HDRT and follow-up per-
iod. The differences in FeNO levels between the groups could
suggest a constitutive susceptibility trait to radiation-induced
Fig. 4. Mean FeNO for the radiation pneumonitis (RP) and non-radiation pneumonitis (non-RP) groups including all patients (A) and excluding patients treated with steroids
during HDRT (B).
Table 2
FeNO measurements at each visit in relation to the grade of radiation pneumonitis.
Mean FeNO ± SD (ppb) CTCAE grade  2 RP CTCAE grade < 2 RP p-value
n = 24 n = 18
Visit 0 (baseline) 15.3 ± 8.6 (95% CI: 11.4–19.2) 11.0 ± 5.2 (95% CI: 8.4–13.6) p = 0.08
Visit 1 (1. week of HDRT) 16.9 ± 11.5 (95% CI: 11.9–21.9) 10.5 ± 5.1 (95% CI: 7.8–13.2) p = 0.03
Visit 2 (2. week of HDRT) 16.6 ± 9.0 (95% CI: 12.7–20.5) 9.8 ± 5.0 (95% CI: 7.4–12.3) p = 0.02
Visit 3 (3. week of HDRT) 14.2 ± 9.6 (95% CI: 10.0–18.4) 9.1 ± 3.7 (95% CI: 7.3–10.9) p = 0.02
Visit 4 (4. week of HDRT) 15.0 ± 7.3 (95% CI: 11.2–18.1) 10.4 ± 4.8 (95% CI: 8.0–12.8) p = 0.03
Visit 5 (5. week of HDRT) 13.4 ± 5.6 (95% CI: 11.0–15.7) 10.6 ± 6.6 (95% CI: 7.3–13.9) p = 0.07
Visit 6 (6. week of HDRT) 14.8 ± 7.5 (95% CI: 11.6–17.9) 10.6 ± 6.7 (95% CI: 7.1–14.0) p = 0.03
Visit 7 (4–6 weeks after visit 6) 17.9 ± 12.2 (95% CI: 12.6–23.2) 10.3 ± 5.4 (95% CI: 7.6–13.0) p = 0.02
Visit 8 (6 months after visit 1) 21.2 ± 17.1 (95% CI: 13.4–28.9) 12.2 ± 7.4 (95% CI: 7.9–16.5) p = 0.01
Visit 9 (9 months after visit 1) 16.7 ± 10.3 (95% CI: 11.6–21.8) 9.0 ± 3.3 (95% CI: 7.0–10.9) p = 0.01
Visit 10 (12 months after visit 1) 20.1 ± 11.1 (95% CI: 13.4–26.9) 12.5 ± 5.5 (95% CI: 8.3–16.8) p = 0.1
FeNO – fractional exhaled nitric oxide; SD – standard deviation; ppb – parts per billion; CTCAE – Common Terminology Criteria for Adverse Events, RP – radiation
pneumonitis; CI – confidence interval; HDRT – high-dose radiation therapy.
Table 3
Dosimetric parameters in relation to radiation pneumonitis.
Parameter CTCAE grade  2 RP CTCAE grade < 2 RP T-test (p-value)
n = 24 n = 18
MLD 14.2 (95%CI: 13,0–15,5) 14.1 (95%CI: 12,2–15,9) T-test (p = 0.86)
V5 (%) 44.0 (95%CI: 39,5–48,6) 43.7 (95%CI: 38,7–48,8) T-test (p = 0.92)
V10 (%) 34.0 (95%CI: 30,5–37,5) 34.3 (95%CI: 30,5–38,2) T-test (p = 0.89)
V20 (%) 28.7 (95%CI: 25,9–31,5) 28.0 (95%CI: 24,6–31,4) T-test (p = 0.75)
V40 (%) 25.2 (95%CI: 22,3–27,4) 24.6 (95%CI: 21,0–28,2) T-test (p = 0.76)
V50 (%) 20.2 (95%CI: 17,9–22,6) 20.0 (95%CI: 16,5–23,5) T-test (p = 0.88)
V60 (%) 14.3 (95%CI: 12,0–16,6) 14.6 (95%CI: 11,4–17,9) T-test (p = 0.88)
CTCAE – Common Terminology Criteria for Adverse Events, RP – radiation pneumonitis; CI – confidence interval; MLD –mean lung dose; V5, 10, 20, 40, 50, 60 (%) - percentage
of lung volume exceeding 5, 10, 20, 40, 50, 60 Gy, respectively.
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to RP development have been described in patients with the
rs189037 variant of the ataxia telangiectasia mutated (ATM)
gene [32]. Similarly, different bronchial airway epithelial gene
expression is correlated with FeNO in patients with various
asthma phenotypes [33].This study reported a rather high incidence of symptomatic RP
compared to the literature. Different scoring methods and the lack
of consensus on the definition of RP have been repeatedly
discussed as a challenge in comparing both the severity and
incidence of RP [34,35]. Several studies used either former version
of CTCAE [7], different scoring systems, such as the Southwest
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apy Oncology Group [3] system or unspecified scales [18,38,39].
Our study strictly followed the CTCAE version 4 grading consider-
ing only the clinical manifestations of radiation-induced lung
injury with promptly steroid treatment at first appearance of
symptoms of RP. The close and frequent monitoring of symptoms
may be a possible explanation of the higher incidence of RP in
our study compared to other retrospective studies or reports from
clinical practice. Another plausible reason for the high RP incidence
in our cohort was the relatively high radiation dose (60–66 Gy)
compared to the average dose or radiation modalities used in other
studies [4,16,40,41].
Smoking status seemed to be negatively correlated with RP,
indicating a protective factor for RP development, similar to other
reports [34,42]. Cigarette smoking leads to hypoxic saturation in
normal and tumor parenchyma, which diminishes the effect of radi-
ation. Therefore, the risk of side effects such as RP is lower. We
observed that active smoking during HDRT influenced measure-
ments of FeNO resulting in false negative and lower values of the
mean FeNO(visit 0-6), limiting its usefulness in prediction of RP.
Our study confirms that PFTs cannot predict the development of
RP. Deterioration in PFTs, abnormal ventilation/perfusion mis-
match and shunt were not correlated with RP. As shown in other
studies [34], repetitive PFTs lack the ability to predict the develop-
ment of RP.
This study reports a higher rate of successful measurements
than other trials [19]. Only one out of fifty patients could not per-
form FeNO measurement, showing that longitudinal FeNO mea-
surements are practically feasible. The measurement method is
robust with high reproducibility, even when performed by differ-
ent operators with stationary or portable devices [19,21,43].
The limitation of the study is a small sample size with possible
impact of few cases on results and conclusions. A possible draw-
back of the method is the precision of <3 ppb for values <30 ppb
[19]. Therefore, the margin of +/3 ppb should be added to the
cut-off value of 14.8 ppb for the mean FeNO(visit 0-6). A mean
FeNO(visit 0-6) less than 14.8 ppb should be interpreted with aware-
ness for the measurement uncertainty.
Weekly measurements of FeNO are feasible during HDRT. A cut-
off value of 14.8 ppb for the mean FeNO(visit 0-6) can be considered
as a potential predictive marker of RP risk. Neither dosimetric
parameters nor PFTs were predictive of RP. Regular clinical
follow-up of at least 6 months is necessary for patients treated
with HDRT in order to detect RP. The results should be further
explored in a randomized trial with steroid treatment introduced
after the end of HDRT in the group of patients with a high mean
FeNO(visit 0-6). Finally, the data indicate a possible genetic suscepti-
bility for RP expressed in differential baseline FeNO levels.
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